Gantrez AN nanoparticles for ocular delivery of memantine: In vitro release evaluation in albino rabbits

Ophthalmic Research

Volumn 48, Issue 3, 2012, Pages 109-117

  Prieto, E ^a   Puente, B ^b   Uixera, A ^b   Garcia De Jalon, J A ^b   Perez, S ^a   Pablo, L ^a   Irache, J M ^c   Garcia, M A ^b   Bregante, M A ^b  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b UNIVERSIDAD DE ZARAGOZA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Gantrez; Memantine; Nanoparticles; Retina

Indexed keywords

GANTREZ COPOLYMER; MEMANTINE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FOLLOW UP; HISTOPATHOLOGY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RABBIT; SCANNING ELECTRON MICROSCOPY; TOXICITY TESTING;

ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; EXCITATORY AMINO ACID ANTAGONISTS; INTRAVITREAL INJECTIONS; MALEATES; MEMANTINE; NANOPARTICLES; PARTICLE SIZE; POLYVINYLS; RABBITS; RETINA; TENON CAPSULE; VITREOUS BODY;

EID: 84860198170     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000337136     Document Type: Article

References (28)

1. Weinreb RN, Khaw PT: Primary open-angle glaucoma. Lancet 2004; 363: 1711-1720. (Pubitemid 38670330)
2. Barkana Y, Belkin M: Neuroprotection in ophthalmology: a review. Brain Res Bull 2004; 62: 447-453. (Pubitemid 38253027)
3. Levin LA, Peeples P: History of neuroprotection and rationale as a therapy for glaucoma. Am J Manag Care 2008; 14:S11-S14. (Pubitemid 351341923)
4. Hare WA, Wheeler L: Experimental glutamatergic excitotoxicity in rabbit retinal ganglion cells: block by memantine. Invest Ophthalmol Vis Sci 2009; 50: 2940-2948.
5. Hare WA, Wolde Mussie E, Lai RK, Ton H, Ruiz G, Chun T, Wheeler L: Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey I-II. Functional measures. Invest Ophthalmol Vis Sci 2004; 2625-2651.
6. Ghate D, Edelhauser H-F: Ocular drug delivery. Expert Opin Drug Deliv 2006; 3: 275.
7. Koevary SB: Trends in the noncorneal delivery of drugs into eye. Arch Soc Esp Oftalmol 2002; 77: 347-349.
8. Raghava S, Hammond M, Kompella U-B: Periocular routes for retinal drug delivery. Expert Opin Drug Deliv 2004; 1: 99-114. (Pubitemid 40297959)
9. Vanrell R: New trends in controlled drug delivery to posterior segment. Arch Soc Esp Oftalmol 2007; 82: 3-5.
10. Hughes PM, Olejnik O, Chang-Lin J, Wilson CG: Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev 2005; 57: 2010-2032. (Pubitemid 41740793)
11. Irache JM: Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini Rev Med Chem 2005; 5: 293-3051.
12. Kohane S: Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng 2007; 96: 203-209.
13. Irache JM, Huici M, Konecny M, Espuelas S, Campanero MA, Arbós P: Bioadhesive properties of Gantrez nanoparticles. Molecules 2005; 10: 126-145. (Pubitemid 40404891)
14. Kompella UB, Bandi N, Ayalasomayajula SP: Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci 2003; 44: 1192-1201. (Pubitemid 36297840)
15. Arbos P, Wirth M, Arangoa MA, Gabor F, Irache JM: Corrigendum to: Gantrez-AN as a new polymer for the preparation of ligandnanoparticles conjugates. J Control Release 2003; 83: 321-330.
16. Arbós P, Wirth M, Arangoa MA, Gabor F, Irache JM: Gantrez-AN as a new polymer for the preparation of ligand-nanoparticle conjugates. J Control Release 2002; 83: 321-330. (Pubitemid 35223255)
17. Benson JR, Hare PE: o -Phthalaldehyde: fluorogenic detection of primary amines in the picomole range. Comparison with fluorescamine and ninhydrin. Proc Natl Acad Sci USA 1975; 72: 619-622.
18. Nuevas formulaciones de memantine encapsulada en nanoparticulas de polianhidrido; master en investigacion quimica, University of Zaragoza, Belen Puente Bayo, 2009.
19. Schneider E, Fischer PA, Clemens R, Balzereit F, Fünfgeld EW, Haase HJ: Effects of oral memantine on symptoms of Parkinson's disease. Results of a placebo-controlled multicenter study. Dtsch Med Wochenschr 2003; 109: 987-990.
20. Ditzler K: Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung 1991; 41: 773-780.
21. Yucel YH, Gupta NG, Zhang S, Mizisin AP, Kalichman MW, Weinreb RN: Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch Ophthamol 2006; 124: 217-225. (Pubitemid 43247073)
22. Puente B, Hernandez E, Perez S, Pablo L, Prieto E, Garcia MA, Bregante MA: Determination of memantine in plasma and vitreous humor by HPLC with precolumn derivatization and fluorescence detection. J Chromatogr Sci 2011; 49: 745-752.
23. Gomez S, Gamazo C, San Roman B, Vauthier C, Ferrer M, Irache JM: Development of a novel vaccine delivery system based on Gantrez nanoparticles. J Nanosci Nanotechnol 2006; 6: 3283-3289. (Pubitemid 44580012)
24. Arbós P, Arangoa M.A, Campanero MA, Irache JM: Quantification of the bioadhesive properties of protein-coated PVM/MA nanoparticles. Int J Pharm 2002; 242: 129-236.
25. Salman H, Gamazo C, Campanero MA, Irache JM: Salmonella-like bioadhesive nanoparticles. J Control Release 2005; 106: 1-13. (Pubitemid 41140076)
26. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM: Intravitreal triamcinoloneinduced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005; 112: 139-143. (Pubitemid 40075333)
27. Cheng L, Hostetler KY, Gardner MF, Avila CP Jr, Bergeron-Lynn G, Keefe KS, Wiley CA, Freeman WR: Intravitreal toxicology in rabbits of two preparations of 1-O-octadecyl-sn-glycerol-3-phosphonoformate, a sustained-delivery anti-CMV drug. Invest Ophthalmol Vis Sci 1999; 40: 1487-1495. (Pubitemid 29252340)
28. Amrite AC, Kompella UB: Size dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol 2005; 57: 1555-1563. (Pubitemid 41752269)